First published on
The calendar signals a new year, but the medtech industry in 2021 will feel the lingering effects, both positive and negative, from the novel coronavirus pandemic.
With the resurgence of the virus and emergence of new, more contagious strains, COVID-19 will have major impacts on companies much as in 2020, albeit with the benefit of insights gleaned from the historic year and its unprecedented business environment.
Earlier this month, medtech and diagnostics companies gathered virtually to discuss 2021 prospects at J.P. Morgan s annual healthcare conference. Executives painted a mixed picture, with the first half of the year looking bumpier than the second half.
Boston
Massachusetts
United-states
John-babbitt
Stephen-macmillan
Alex-nowak
Geoff-martha
Doug-bryant
Robert-ford
Abbott-ford
Joe-almeida
Mike-mahoney